IL251246A0 - Therapeutically active compounds and methods of use - Google Patents

Therapeutically active compounds and methods of use

Info

Publication number
IL251246A0
IL251246A0 IL251246A IL25124617A IL251246A0 IL 251246 A0 IL251246 A0 IL 251246A0 IL 251246 A IL251246 A IL 251246A IL 25124617 A IL25124617 A IL 25124617A IL 251246 A0 IL251246 A0 IL 251246A0
Authority
IL
Israel
Prior art keywords
methods
active compounds
therapeutically active
therapeutically
compounds
Prior art date
Application number
IL251246A
Other languages
English (en)
Hebrew (he)
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of IL251246A0 publication Critical patent/IL251246A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL251246A 2014-09-29 2017-03-17 Therapeutically active compounds and methods of use IL251246A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462056996P 2014-09-29 2014-09-29
PCT/US2015/052598 WO2016053850A1 (en) 2014-09-29 2015-09-28 Therapeutically active compounds and their methods of use

Publications (1)

Publication Number Publication Date
IL251246A0 true IL251246A0 (en) 2017-05-29

Family

ID=54289133

Family Applications (1)

Application Number Title Priority Date Filing Date
IL251246A IL251246A0 (en) 2014-09-29 2017-03-17 Therapeutically active compounds and methods of use

Country Status (8)

Country Link
US (3) US9694013B2 (enExample)
EP (1) EP3200800A1 (enExample)
JP (2) JP2017529382A (enExample)
KR (1) KR20170057411A (enExample)
AU (1) AU2015324158A1 (enExample)
CA (1) CA2962943A1 (enExample)
IL (1) IL251246A0 (enExample)
WO (1) WO2016053850A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20160840A1 (es) 2013-08-02 2016-09-22 Agios Pharmaceuticals Inc Formas cristalinas de compuestos inhibidores de isocitrato deshidrogenasa 2 (idh2)
KR20170057411A (ko) 2014-09-29 2017-05-24 아지오스 파마슈티컬스 아이엔씨. 치료적 활성 화합물 및 이들의 사용 방법
KR102628370B1 (ko) * 2015-02-04 2024-01-24 르 라보레또레 쎄르비에르 치료적 활성 화합물 및 이들의 사용 방법
AU2016303614A1 (en) 2015-08-05 2018-02-15 Agios Pharmaceuticals, Inc. Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines
US10905692B2 (en) 2015-10-15 2021-02-02 Agios Pharmaceuticals, Inc. Combination therapy for treating malignancies
JP6895956B2 (ja) 2015-10-15 2021-06-30 セルジーン コーポレイション 悪性腫瘍を治療するための併用療法
MA43374A (fr) 2015-12-04 2018-10-10 Agios Pharmaceuticals Inc Méthodes de traitement de tumeurs malignes
EP3419593B1 (en) * 2016-02-26 2022-03-23 Celgene Corporation Enasidenib for use in the treatment of relapsed or refractory acute myeloid leukaemia
WO2018010142A1 (en) * 2016-07-14 2018-01-18 Shanghai Meton Pharmaceutical Co., Ltd Iso-citrate dehydrogenase (idh) inhibitor
US11389454B2 (en) * 2016-09-07 2022-07-19 Celgene Corporation Tablet compositions
US11229653B2 (en) 2017-05-05 2022-01-25 Celgene Corporation Methods of treatment of myeloproliferative neoplasm
JP7306634B2 (ja) * 2017-10-19 2023-07-11 一般社団法人ファルマバレープロジェクト支援機構 Ｉｄｏ／ｔｄｏ阻害剤
AU2018375308A1 (en) * 2017-11-29 2020-06-25 The Rockefeller University Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases
US12215094B2 (en) 2018-11-02 2025-02-04 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
WO2020092915A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
US20220017490A1 (en) 2018-11-02 2022-01-20 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
WO2020239759A1 (en) * 2019-05-27 2020-12-03 Sandoz Ag Amorphous enasidenib in a stabilized form
JP2023503842A (ja) * 2019-11-14 2023-02-01 セルジーン コーポレーション がんを処置するための小児用製剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2860623A1 (en) 2012-01-06 2013-07-11 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
SG11201600058XA (en) 2013-07-11 2016-02-26 Agios Pharmaceuticals Inc N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
PE20160840A1 (es) 2013-08-02 2016-09-22 Agios Pharmaceuticals Inc Formas cristalinas de compuestos inhibidores de isocitrato deshidrogenasa 2 (idh2)
KR20170057411A (ko) * 2014-09-29 2017-05-24 아지오스 파마슈티컬스 아이엔씨. 치료적 활성 화합물 및 이들의 사용 방법
KR102628370B1 (ko) 2015-02-04 2024-01-24 르 라보레또레 쎄르비에르 치료적 활성 화합물 및 이들의 사용 방법
AU2016303614A1 (en) 2015-08-05 2018-02-15 Agios Pharmaceuticals, Inc. Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines
US10905692B2 (en) 2015-10-15 2021-02-02 Agios Pharmaceuticals, Inc. Combination therapy for treating malignancies
MA43374A (fr) 2015-12-04 2018-10-10 Agios Pharmaceuticals Inc Méthodes de traitement de tumeurs malignes
EP3419593B1 (en) 2016-02-26 2022-03-23 Celgene Corporation Enasidenib for use in the treatment of relapsed or refractory acute myeloid leukaemia

Also Published As

Publication number Publication date
CA2962943A1 (en) 2016-04-07
US20160089374A1 (en) 2016-03-31
US10105369B2 (en) 2018-10-23
US9694013B2 (en) 2017-07-04
EP3200800A1 (en) 2017-08-09
KR20170057411A (ko) 2017-05-24
JP2017529382A (ja) 2017-10-05
AU2015324158A1 (en) 2017-04-13
US20180125850A1 (en) 2018-05-10
WO2016053850A1 (en) 2016-04-07
JP2020147571A (ja) 2020-09-17
US20170266193A1 (en) 2017-09-21
US9889137B2 (en) 2018-02-13

Similar Documents

Publication Publication Date Title
IL286316A (en) New micro-dystrophins and related method of use
IL270347B (en) Therapeutically active compounds and methods of use
IL251246A0 (en) Therapeutically active compounds and methods of use
IL253796A0 (en) Therapeutically active compounds and methods of use
IL250415B (en) Antibodies against pd-l and methods of using them
IL258768A (en) Compounds interacting with glycans and methods of use
ZA201600667B (en) Therapeutically active compounds and their methods of use
GB201403093D0 (en) Therapeutic compounds and their use
HUE068842T2 (hu) Vegyületek és alkalmazási eljárásaik
ZA201605639B (en) Hppd variants and methods of use
GB201418350D0 (en) Dispenser and methods of use thereof
HUE061672T2 (hu) Glikán-interakcióban lévõ vegyületek és felhasználási módszerek
PT3089971T (pt) Compostos e métodos de utilização
ZA201606243B (en) Hppd variants and methods of use
IL265955A (en) Therapeutic compounds and methods of using them
IL254783B (en) Combinations for deworming methods for using them
SG11201605915WA (en) Furo-3-carboxamide derivatives and methods of use
ZA201802134B (en) Therapeutic compounds and methods of use thereof
ZA201606450B (en) Compounds and their methods of use
GB201403697D0 (en) Compounds and methods of use
ZA201700571B (en) Therapeutically active compounds and their methods of use
EP3212202A4 (en) Use of therapeutic agents
AU2014904330A0 (en) Use of therapeutic agents
GB201410387D0 (en) Compounds and their therapeutic use
GB201403496D0 (en) Compounds and their therapeutic use